MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS

Biomedicine & Pharmacotherapy - Tập 119 - Trang 109424 - 2019
Fei Xie1, Chuan Li1, Xiaoyun Zhang1, Wei Peng1, Tianfu Wen1
1Department of Liver Surgery & Liver Transplantation Centre, West China Hospital of Sichuan University, Chengdu 610041, China

Tài liệu tham khảo

Siegel, 2019, Cancer statistics, 2019, CA Cancer J. Clin., 69, 7, 10.3322/caac.21551

Hammad, 2019

Noel, 2019, Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma, Invest. New Drugs, 10.1007/s10637-019-00830-3

Karamitopoulou, 2019, Clinical scenarios emerging from combined immunophenotypic, molecular and morphologic analysis of pancreatic Cancer: the good, the bad and the ugly scenario, Cancers (Basel), 11, 10.3390/cancers11070968

Bartel, 2009, MicroRNAs: target recognition and regulatory functions, Cell, 136, 215, 10.1016/j.cell.2009.01.002

Rupaimoole, 2017, MicroRNA therapeutics: towards a new era for the management of cancer and other diseases, Nat. Rev. Drug Discov., 16, 203, 10.1038/nrd.2016.246

Li, 2017, miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells, Am. J. Transl. Res., 9, 2276

Shi, 2018, MiR-143-3p suppresses the progression of ovarian cancer, Am. J. Transl. Res., 10, 866

Ding, 2019, MicroRNA-143-3p suppresses tumorigenesis by targeting catenin-delta1 in colorectal cancer, Onco. Ther., 12, 3255, 10.2147/OTT.S184118

Bai, 2016, Down-regulation of microRNA-143 is associated with colorectal cancer progression, Eur. Rev. Med. Pharmacol. Sci., 20, 4682

Su, 2014, MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer, PLoS One, 9, 10.1371/journal.pone.0114420

Han, 2018, MiR-143-3p suppresses cell proliferation, migration, and invasion by targeting Melanoma-Associated Antigen A9 in laryngeal squamous cell carcinoma, J. Cell. Biochem.

Kim, 2017, Rules for functional microRNA targeting, BMB Rep., 50, 554, 10.5483/BMBRep.2017.50.11.179

Jin, 2018, miR-143-3p targeting of ITGA6 suppresses tumour growth and angiogenesis by downregulating PLGF expression via the PI3K/AKT pathway in gallbladder carcinoma, Cell Death Dis., 9, 182, 10.1038/s41419-017-0258-2

Abreu, 2017, miRNA analysis in pancreatic cancer: the Dartmouth experience, Clin. Chem. Lab. Med., 55, 755, 10.1515/cclm-2017-0046

Zhu, 2019, Differential MicroRNA expression profiles as potential biomarkers for pancreatic ductal adenocarcinoma, Biochemistry (Mosc.), 84, 575, 10.1134/S0006297919050122

Diaz-Riascos, 2019, Expression and role of MicroRNAs from the miR-200 family in the tumor formation and metastatic propensity of pancreatic Cancer, Mol. Ther. Nucleic Acids, 17, 491, 10.1016/j.omtn.2019.06.015

Madurantakam, 2019, miRNA predictors of pancreatic Cancer Chemotherapeutic response: a systematic review and meta-analysis, Cancers (Basel), 11

Hou, 2019, Mechanism of miR-143-3p inhibiting proliferation, migration and invasion of osteosarcoma cells by targeting MAPK7, Artif. Cells Nanomed. Biotechnol., 47, 2065, 10.1080/21691401.2019.1620252

Jin, 2018, miR-143-3p targeting of ITGA6 suppresses tumour growth and angiogenesis by downregulating PLGF expression via the PI3K/AKT pathway in gallbladder carcinoma, Cell Death Dis., 9, 182, 10.1038/s41419-017-0258-2

Stewart, 2015, Clinical significance of the integrin alpha6beta4 in human malignancies, Lab. Invest., 95, 976, 10.1038/labinvest.2015.82

Collins, 2013, Kras as a key oncogene and therapeutic target in pancreatic cancer, Front. Physiol., 4, 407

Kimmelman, 2015, Metabolic dependencies in RAS-Driven cancers, Clin. Cancer Res., 21, 1828, 10.1158/1078-0432.CCR-14-2425

Wang, 2019, Mu-KRAS attenuates Hippo signaling pathway through PKCiota to sustain the growth of pancreatic cancer, J. Cell. Physiol.

Wu, 2018, MiR-216b inhibits pancreatic cancer cell progression and promotes apoptosis by down-regulating KRAS, Arch. Med. Sci., 14, 1321, 10.5114/aoms.2018.72564

Vena, 2015, The MEK1/2 inhibitor pimasertib enhances gemcitabine efficacy in pancreatic Cancer models by altering ribonucleotide reductase Subunit-1 (RRM1), Clin. Cancer Res., 21, 5563, 10.1158/1078-0432.CCR-15-0485

Dhillon, 2007, MAP kinase signalling pathways in cancer, Oncogene, 26, 3279, 10.1038/sj.onc.1210421

Thông tin
Thông tin xuất bản

Biomedicine & Pharmacotherapy

Tập 119

109424

Thông tin tác giả